Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

Diabetes, Obesity and Metabolism

Volumn 14, Issue 11, 2012, Pages 990-999

  Ljunggren, O ^a   Bolinder, J ^b   Johansson, L ^a,c   Wilding, J ^d   Langkilde, A M ^c   Sjostrom C D ^c   Sugg, J ^e   Parikh, S ^e  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Body composition; Clinical trial; Renal glucose handling; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; C TERMINAL CROSS LINKING TELOPEPTIDE OF TYPE I COLLAGEN; DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT; BONE DENSITY; BREAST CANCER; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGUS VARICES BLEEDING; FEMALE; FRACTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOLYSIS; PNEUMONIA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SPONDYLOSIS; TRANSIENT GLOBAL AMNESIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VERTIGO;

EID: 84867142771     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01630.x     Document Type: Article

References (33)

1. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
2. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
3. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
4. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
5. Strojek K, Yoon K, Hruba V, Elze M, Langkilde A, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
6. Rosenstock J, Vico M, Wei L, Salsali A, List J. Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes (Abstract 986-P). Diabetes 2011; 60(Suppl. 1): A270.
7. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
8. Wilding JPH, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-415.
9. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
10. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
11. Ricci TA, Heymsfield SB, Pierson RN Jr, Stahl T, Chowdhury HA, Shapses SA. Moderate energy restriction increases bone resorption in obese postmenopausal women. Am J Clin Nutr 2001; 73: 347-352.
12. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
13. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
14. Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. J Bone Joint Surg Am 2010; 92: 743-753.
15. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007; 18: 427-444.
16. Dennison EM, Syddall HE, Aihie Sayer A, Craighead S, Phillips DI, Cooper C. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? Diabetologia 2004; 47: 1963-1968.
17. Oz SG, Guven GS, Kilicarslan A, Calik N, Beyazit Y, Sozen T. Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl Med Assoc 2006; 98: 1598-1604.
18. Akin O, Gol K, Akturk M, Erkaya S. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol 2003; 17: 19-29.
19. Isidro ML, Ruano B. Bone disease in diabetes. Curr Diabetes Rev 2010; 6: 144-155.
20. Khazai NB, Beck GR Jr, Umpierrez GE. Diabetes and fractures: an overshadowed association. Curr Opin Endocrinol Diabetes Obes 2009; 16: 435-445.
21. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005; 16: 1713-1720.
22. Schwartz AV, Vittinghoff E, Bauer DC et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305: 2184-2192.
23. Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPAR-γ activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011; 152: 457-467.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
25. Roche Diagnostics Ltd. Elecsys and cobas e analyzers: total P1NP, V7 English, 2010.
26. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008; 54: 188-196.
27. Roche Diagnostics Ltd. Elecsys and cobas e analyzers: β-CrossLaps/serum, V8 English, 2007.
28. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001; 47: 694-702.
29. The International Society for Clinical Densitometry. 2007 Official Positions. Available from URL: http://www.iscd.org/Visitors/pdfs/ISCD2007OfficialPositions-Adult.pdf. Accessed 4 July 2011.
30. Zhang M, Tsiatis AA, Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics 2008; 64: 707-715.
31. Schwartz AV, Vittinghoff E, Sellmeyer DE et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008; 31: 391-396.
32. Schwartz AV, Garnero P, Hillier TA et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 2380-2386.
33. Garris DR, Burkemper KM, Garris BL. Influences of diabetes (db/db), obese (ob/ob) and dystrophic (dy/dy) genotype mutations on hind limb bone maturation: a morphometric, radiological and cytochemical indices analysis. Diabetes Obes Metab 2007; 9: 311-322.